RxDoctor Payments Data

Donald Brislin, DO

Internal Medicine · Dublin, PANPI 1649294620

Payments from drug & device makers

$433in general payments, 2019–2025

Across 32 payments — averaging $13.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$148
  • Novo Nordisk$75
  • Boehringer Ingelheim$46
  • Lilly USA, LLC$27
  • Merck$26
  • Johnson & Johnson$24
  • plus $89 from 6 others

What the payments were for

  • Food & beverage$41295%
  • Education$215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$433 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$80,195
Medicare patients
190
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$39,838
OzempicSemaglutide17$37,134
TrulicityDulaglutide35$37,103
JanuviaSitagliptin Phosphate60$35,753
EliquisApixaban42$23,733
XareltoRivaroxaban30$21,989
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,216
JanumetSitagliptin Phos/Metformin Hcl17$13,732
FarxigaDapagliflozin Propanediol23$12,881
Breo ElliptaFluticasone/Vilanterol18$7,692
Lansoprazole12$6,656
MyrbetriqMirabegron54$6,578
Levothyroxine Sodium468$5,966
Rosuvastatin Calcium193$5,612
Dexlansoprazole DrDexlansoprazole17$3,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$26$49,48577 claims
Boehringer IngelheimJardiance$46$39,83852 claims
Novo NordiskOzempic$75$37,13417 claims
Lilly USA, LLCTrulicity$27$37,10335 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$12$27,56647 claims
PfizerEliquis$12$23,73342 claims
Johnson & JohnsonXarelto$24$21,98930 claims
AstraZenecaFarxiga$148$12,88123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Dublin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →